• Profile
Close

Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS randomized clinical trial

JAMA Jul 20, 2018

Khatri P, et al. - In patients with National Institutes of Health Stroke Scale (NIHSS) scores of 0 to 5 whose deficits are not clearly disabling, the efficacy and safety of alteplase were evaluated. Findings suggested that treatment with alteplase vs aspirin did not increase the odds of favorable functional outcome at 90 days in patients with minor nondisabling acute ischemic stroke. However, the very early study termination precludes any definitive conclusions.

Methods

  • The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial comparing alteplase with aspirin for emergent stroke at 75 stroke hospital networks in the US.
  • Subjects with acute ischemic stroke whose deficits were scored as 0 to 5 on the NIHSS and judged not clearly disabling and in whom study treatment could be started within 3 hours of onset were qualified and enlisted from May 30, 2014 to December 20, 2016, with final follow-up on March 22, 2017.
  • After that, patients were randomly allocated to receive intravenous alteplase at the standard dose (0.9 mg/kg) with oral placebo (n=156) or oral aspirin, 325 mg, with intravenous placebo (n=157).
  • The primary outcome was the difference in favorable functional outcome, characterized as a modified Rankin Scale score of 0 or 1 at 90 days through Cochran-Mantel-Haenszel test stratified by pretreatment NIHSS score, age, and time from onset to treatment.
  • Due to early termination of the trial, before unblinding or interim analyses, the revised plan was to investigate the risk difference of the primary outcome by a linear model adjusted for the same factors.
  • Symptomatic intracranial hemorrhage (sICH) within 36 hours of intravenous study treatment was the primary safety end point.

Results

  • The study results showed that among 313 patients enlisted at 53 stroke networks (mean age, 62 [SD, 13] years; 144 [46%] women; median NIHSS score, 2 [interquartile range {IQR}, 1-3]; median time to treatment, 2.7 hours [IQR, 2.1-2.9]), 281 (89.8%) finished the trial.
  • It was observed that 122 patients (78.2%) in the alteplase group vs 128 (81.5%) in the aspirin group achieved a favorable outcome (adjusted risk difference, -1.1%; 95% CI, -9.4% to 7.3%) at 90 days.
  • Findings revealed that 5 alteplase-treated patients (3.2%) vs 0 aspirin-treated patients had sICH (risk difference, 3.3%; 95% CI, 0.8%-7.4%).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay